Competitive Entry into the MucoUp Market
First written in FY2020-Q1. 2 of 11 entries say "Materialised", first in FY2020-Q2. Latest entry: FY2024-Q3.
Seikagaku moved to the "Worse" side of this theme in 2019, 3 years before the typical company in this theme (2022).
The whole theme swung hardest in 2025: 4 of 7 companies on the "Worse" side.
9 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「The company's sales of MucoUp, an endoscopic submucosal injection material, increased because of inventory adjustments by the sales partner.」
The situation in which inventory adjustments by the sales partner affect our revenue from Mucoup continued, and this quarter they appeared as a factor driving revenue growth. - FY2024-Q2MitigatedAnnual report
「The company's sales of MucoUp, an endoscopic submucosal injection material, increased because of inventory adjustments by the sales partner.」
The previous quarter's decline in revenue due to inventory adjustments by the sales partner turned into a revenue increase this quarter as the same inventory-adjustment factor. There was no new disclosure indicating an impact from the entry of competing products. - FY2024-Q1Revenue declined due to inventory adjustments by the sales partnerAnnual report
「Mucoup, a submucosal injection agent for endoscopic procedures, was affected by inventory adjustments by our sales partner, and our revenue declined.」
Unlike the previous impact of competing products, our revenue from Mucoup declined this quarter due to inventory adjustments by our sales partner. - FY2023-Q2Revenue declined due to a rebound from high prior-year shipments and a revision of reimbursement pricesAnnual report
「Mucoup, a submucosal injection agent for endoscopic procedures, was affected by a rebound from the high level of shipments in the same period of the previous year, as well as by the impact of a revision of reimbursement prices, and our revenue declined.」
Our revenue from Mucoup declined due to a rebound from shipments in the same period of the previous year and the impact of a revision of reimbursement prices. - FY2023-Q1Revenue increased due to a rebound from lower shipments in the previous yearAnnual report
「Mucoup, a submucosal injection agent for endoscopic procedures, saw our revenue increase as a rebound from the low level of shipments in the same period of the previous year.」
Our revenue from Mucoup increased as a rebound from the low level of shipments in the same period of the previous year. There was no new disclosure regarding the impact of competing products. - FY2022Revenue remained at the previous-period level due to inventory adjustmentsAnnual report
「Although Mucoup benefited from a rebound from the impact of the spread of COVID-19 in the previous period, inventory adjustments by our sales partner resulted in our revenue remaining at the previous-period level.」
Mucoup had continued to post lower revenue due to the impact of competing products. Although there was a rebound from the impact of infectious disease, inventory adjustments by our sales partner resulted in our revenue remaining at the previous-period level. - FY2021-Q2WorsenedAnnual report
「Mucoup, a submucosal injection agent for endoscopic procedures, was affected by the aggressive marketing of competing products through a low-price strategy, as well as by a decline in the number of endoscopic procedures accompanying the spread of COVID-19, and our revenue declined.」
In addition to the existing impact and aggressive marketing of competing products, Mucoup continued to experience lower revenue due to the low-price strategy of competing products and the decline in the number of endoscopic procedures. - FY2021-Q1WorsenedAnnual report
「Mucoup, a submucosal injection agent for endoscopic procedures, was affected by the entry and aggressive marketing of competing products, as well as by a decline in the number of endoscopic procedures accompanying the spread of COVID-19, and our revenue declined.」
In addition to the existing revenue pressure from the entry and aggressive marketing of competing products, Mucoup was affected by a decline in the number of endoscopic procedures due to the spread of infectious disease, resulting in lower revenue for our company. - FY2020-Q3MaterialisedAnnual report
「Mucoup, a submucosal injection agent for endoscopic procedures, was affected by the entry of competing products, and our revenue declined.」
The continued entry of competing products for Mucoup was reflected in the cumulative third-quarter results as a decline in our revenue. - FY2020-Q2MaterialisedAnnual report
「Mucoup, a submucosal injection agent for endoscopic procedures, was affected by the entry of competing products, and our revenue declined.」
The entry of competing products for Mucoup continued to be reflected in the results as a decline in our revenue. - FY2020-Q1First statedAnnual report
「Mucoup, a submucosal injection agent for endoscopic procedures, was affected by the entry of competing products, and our revenue declined.」
For Mucoup, the entry of competing products was identified for the first time as a factor behind the decline in our revenue.